for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Open Orphan PLC

ORPH.L

Latest Trade

45.00GBp

Change

2.05(+4.77%)

Volume

11,936,007

Today's Range

44.00

 - 

46.00

52 Week Range

6.50

 - 

48.00

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Latest Developments

Open Orphan Says Unit Enter Into Contract With Biotechnology Company

March 26 (Reuters) - Open Orphan PLC <ORPH.L>::£7.5M HUMAN CHALLENGE STUDY CONTRACT.UNIT, HVIVO, ENTERED INTO CONTRACT WITH A BIOTECHNOLOGY COMPANY.CONTRACT TO RUN A HUMAN VIRAL CHALLENGE STUDY FOR A RESPIRATORY SYNCYTIAL VIRUS PROPHYLACTIC AND TREATMENT.

Open Orphan Announces New Contract Win With Oxford BioTherapeutics

March 9 (Reuters) - Open Orphan PLC <ORPH.L>::OPEN ORPHAN PLC - NEW CONTRACT WIN WITH OXFORD BIOTHERAPEUTICS.

Open Orphan Extends Contract With Carna Biosciences

Feb 1 (Reuters) - Open Orphan PLC <ORPH.L>::OPEN ORPHAN PLC - CONTRACT EXTENSION WITH CARNA BIOSCIENCES.OPEN ORPHAN - FURTHER CONTRACT RENEWAL WITH CARNA BIOSCIENCES, EXTENDING INTEGRATED DRUG DEVELOPMENT CONSULTANCY SERVICES WITH VENN LIFE SCIENCES.

Open Orphan Says First Volunteer Dosed In Covid-19 Clinical Trial With Codagenix

Jan 11 (Reuters) - Open Orphan PLC <ORPH.L>::OPEN ORPHAN PLC - FIRST VOLUNTEER DOSED IN COVID-19 CLINICAL TRIAL.OPEN ORPHAN PLC - FIRST VOLUNTEER HAS BEEN DOSED WITH CODAGENIX INC. NEEDLE FREE, INTRANASAL COVID-19 VACCINE, COVI-VAC.

Open Orphan Renews Contract With Top-3 Pharmaceutical Client

Jan 6 (Reuters) - Open Orphan PLC <ORPH.L>::OPEN ORPHAN PLC - CONTRACT RENEWAL WITH TOP-3 PHARMACEUTICAL CLIENT.

Open Orphan Says Contract Renewal With Top-3 Pharmaceutical Client

Dec 22 (Reuters) - Open Orphan PLC <ORPH.L>::OPEN ORPHAN PLC - CONTRACT RENEWAL WITH TOP-3 PHARMACEUTICAL CLIENT.

Open Orphan Announces MHRA Nod For Nasal COVID-19 Vaccine Trial

Dec 14 (Reuters) - Open Orphan PLC <ORPH.L>::OPEN ORPHAN PLC - MHRA APPROVAL FOR NASAL COVID-19 VACCINE TRIAL.OPEN ORPHAN PLC - FIRST IN HUMAN (PHASE I) STUDY OF CODAGENIX INTRANASAL SARS-COV-2 (COVID-19) VACCINE CANDIDATE HAS RECEIVED APPROVAL FROM UK.OPEN ORPHAN PLC - HVIVO, PART OF OPEN ORPHAN PLC, IS WORKING IN COLLABORATION WITH US BIOTECH CODAGENIX TO CONDUCT PHASE I STUDY OF COVI-VAC.OPEN ORPHAN PLC - HVIVO EXPECTS STUDY TO COMMENCE IN JANUARY 2021, INITIAL DATA EXPECTED IN EARLY Q2 2020.

Open Orphan Says First Contract Is A COVID-19 Study For European Pharmaceutical Co

Dec 7 (Reuters) - Open Orphan PLC <ORPH.L>::VENN LIFE SCIENCES CONTRACT WINS.FIRST CONTRACT, WHICH WILL COMMENCE IMMEDIATELY, IS A COVID-19 STUDY FOR A EUROPEAN PHARMACEUTICAL COMPANY.

Open Orphan Says Collaboration With Hic-Vac And Wellcome Trust

Nov 19 (Reuters) - Open Orphan PLC <ORPH.L>::OPEN ORPHAN PLC - COLLABORATION WITH HIC-VAC AND WELLCOME TRUST.

Open Orphan Announces New 2.5 Mln Stg Influenza Challenge Study Contract Win

Nov 5 (Reuters) - Open Orphan PLC <ORPH.L>::OPEN ORPHAN PLC - NEW £2.5M INFLUENZA CHALLENGE STUDY CONTRACT WIN.OPEN ORPHAN - SIGNING OF £2.5 MILLION CONTRACT BY HVIVO, SUBSIDIARY OF OPEN ORPHAN, TO CONDUCT INFLUENZA HUMAN CHALLENGE STUDY WITH US BIOTECHNOLOGY CO.OPEN ORPHAN - STUDY IS EXPECTED TO COMMENCE AT HVIVO'S 24-BEDROOM QUARANTINE CLINIC IN EAST LONDON IN H2 2021 AND BE FULLY COMPLETED BY YEAR END 2021.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up